FSL-1 TFA

FSL-1 TFA; 纯度: 99.58%

FSL-1 TFA 是细菌衍生的一种 Toll 样受体 2/6 (TLR2/6) 激动剂,可增强对 HSV-2 感染的抵抗力。FSL-1 TFA 通过 TLR2NF-κB/AP-1 信号通路诱导 MMP-9 产生。

FSL-1 TFAamp;;

FSL-1 TFA Chemical Structure

规格 价格 是否有货 数量
100 μg ¥1600 In-stock

* Please select Quantity before adding items.

生物活性

FSL-1 TFA, a bacterial-derived toll-like receptor 2/6 (TLR2/6) agonist, enhances resistance to experimental HSV-2 infection[1]. FSL-1 TFA induces MMP-9 production through TLR2 and NF-κB/AP-1 signaling pathways in monocytic THP-1 cells[2].

IC50 Target[1][2]

TLR2

;

TLR6

;

MMP-9

;

体外研究
(In Vitro)

FSL-1 significantly reduces HSV-2 replication in human vaginal epithelial cells (EC)[1].
FSL-1 induces significant resistance to experimental genital HSV-2 infection through elaboration of a specific cytokine response profile[1].
FSL-1 (50 ng/mL, 24 hours) induces MMP-9 expression at both mRNA and protein levels in human monocytic THP-1 cells[2].
FSL-1 activates the MAP kinase/NF-κB signaling pathway[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: V11I, V12I or V19I immortalized human vaginal EC
Concentration: 6 μg or 0.1 μg
Incubation Time: Added at 24, 6 or just prior to HSV-2 inoculation (104pfu/well)
Result: The 6 μg does produced significant reductions when delivered at 24 or 6 h prior to HSV-2 inoculation. The 0.1 μg dose produced reduced HSV-2 replication at 24 or 6 h prior to viral challenge.

体内研究
(In Vivo)

FSL-1 application significantly protectes against genital HSV-2 challenge in mice[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female Swiss-Webster mice (weighing 20-25 g)[1]
Dosage: 2 or 6 μg
Administration: Delivered vaginally using a positive displacement pipet, prior to or following viral challenge as specified for each experiment.
Result: The 2 μg does delivered 6 h prior to HSV-2 challenge increased the ID50 (260 pfu) and LD50 (660 pfu) by 10-fold compared to DPBS vehicle control.
The single 6 μg dose produced significantly improved outcomes compared to DPBS vehicle application.

分子量

1780.18

Formula

C82H141F3N14O20S

Sequence Shortening

S-(2, 3-Bispalmitoyloxypropyl)-CGDPKHPKSF

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture and light

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture and light)

Solvent Solubility
In Vitro:;

H2O

Peptide Solubility and Storage Guidelines:

1.;;Calculate the length of the peptide.

2.;;Calculate the overall charge of the entire peptide according to the following table:

; Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.;;Recommended solution:

Overall charge of peptide Details
Negative (lt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, add NH4OH (lt;50 μL).
3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (gt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献
  • [1]. William A Rose 2nd, et al. FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection. Virol J. 2009 Nov 10;6:195.

    [2]. Cathryn J Kurkjian,et al. The Toll-Like Receptor 2/6 Agonist, FSL-1 Lipopeptide, Therapeutically Mitigates Acute Radiation Syndrome. Sci Rep. 2017 Dec 11;7(1):17355.

发表回复